MedTrace Logo

Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer

NCT03052621 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2017-02-14

No results posted yet for this study

Summary

Locally advance breast cancer and extensive locoregional recurrence are still considered as complexity of reconstruction. Although previous studies concluded that omental transposition was considerably indicated in poor vascularity in irradiated tissue, secondary infection and large defect become the obstacles of local tissue flaps. While some centres showed the excellent healing of omental transposition. Meanwhile, many studies showed the preferable outcome in escalating radiotherapy in term of locoregional control. In the investigators' institute, omental transposition in breast cancer has been developed for twenty years. The only institute in Thailand enhanced using this procedure in order to closure of large primary breast cancer and chest wall recurrence. This procedure is undertaken by single surgeon (Dr. K.J.). The investigators' protocol of omental transposition is including preoperative chemotherapy, preoperative accelerated radiation up to 80 Gy, approval of breast cancer centre committee, and meticulous wound care including vacuum assisted wound dressing, non-adhesive dressing. As a result, survival time could be improved.

Conditions

  • Survival Rate

Interventions

PROCEDURE

Omental transposition

Harvesting the omentum to cover irradiated defects of breast cancer

Sponsors & Collaborators

  • Queen Sirikit Centre for Breast Cancer

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-01-31
Primary Completion
2016-10-31
Completion
2016-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052621 on ClinicalTrials.gov